Share This Page
Drugs in ATC Class H05AA
✉ Email this page to a colleague
Drugs in ATC Class: H05AA - Parathyroid hormones and analogues
| Tradename | Generic Name |
|---|---|
| BONSITY | teriparatide |
| FORTEO | teriparatide |
| TERIPARATIDE | teriparatide |
| PARATHAR | teriparatide acetate |
| TYMLOS | abaloparatide |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class H05AA: parathyroid hormones and analogues
ATC H05AA (parathyroid hormones and analogues) is dominated commercially by teriparatide (PTH 1-34), teriparatide injection biosimilars where approved, and abaloparatide (PTHrP analog). The patent estate for core products is largely transition-driven: first by expiry of composition and use patents, then by method-of-manufacture and formulation/ device patents that control long-acting delivery formats, dosing regimens, and pen/ device-integrated usability. Competitive risk for next launches is highest for line extensions with the closest dosing and use-label scope, and for biosimilar/“follow-on” development that can navigate remaining patent-protected attributes (device, excipient system, stabilization, and manufacturing controls).
What is the current commercial market for ATC H05AA parathyroid hormones and analogues?
Answer (featured snippet): Market dynamics in H05AA are concentrated in teriparatide and abaloparatide for osteoporosis indications, with additional demand tied to hypoparathyroidism and other off-label/label-adjacent uses depending on geography.
Key revenue drivers by molecule
- Teriparatide (PTH 1-34): long-standing standard for osteoporosis in high-risk patients, with demand sustained by chronic, adherence-linked use via pen delivery and established care pathways.
- Abaloparatide (PTHrP analog): targets a similar osteoporosis population; commercial share depends on payer preference, formulary restrictions, and persistence/adherence.
- Other H05AA-active agents (jurisdiction-dependent): market size is smaller and more local, affecting how often patent challenges become commercially material.
Demand structure that shapes patent value
- Indication breadth: broader label coverage increases the “claim chart surface area” for method-of-use patents and dosing/regimen patents.
- Reimbursement and switching incentives: payers push toward lower-cost alternatives after exclusivity, increasing urgency for biosimilar/generic entry strategies.
- Device and usability: pen ergonomics and injection cadence drive persistence, making device/formulation patents commercially relevant even after composition expiry.
Competitive set (practical view)
- “Follow-on” pressure is strongest where:
- the reference product’s exclusivity wall is down (composition and core use),
- there is no remaining Orange Book bottleneck for the exact formulation and dosing,
- and device/form factor patents are either expired or designed around.
Which patents protect teriparatide and its analogs in ATC H05AA?
Answer (featured snippet): The practical patent moat around teriparatide-like products usually clusters into (1) composition or PTH fragment definitions, (2) therapeutic use or dosing regimen, and (3) formulation/stabilization plus delivery device integration.
Patent buckets that matter for H05AA
1) Composition of matter and analog definitions
- Claims typically cover:
- PTH(1-34) peptide itself or specific analog sequences,
- salts/hydrates and stability forms,
- and sometimes specific post-translational or synthetic variants.
2) Method of treatment and dosing regimen
- Claims commonly cover:
- administration schedules (daily dosing),
- patient subsets (high fracture risk criteria),
- and treatment duration windows or sequencing relative to antiresorptives.
3) Formulation patents
- Stabilization is a recurring claim theme:
- peptide stabilization systems,
- buffering range and ionic strength,
- preservatives or preservative-free architecture,
- and surfactant/excipient selection to control aggregation, adsorption, and viscosity.
4) Device and delivery system patents
- For pen injectors and cartridges:
- drug container geometry and material compatibility,
- dosing mechanism tolerances,
- needle interface and flow path design,
- and usability features that can support non-obvious design-around.
Litigation-relevant claim targets
- The biggest entry-risk areas for generics/biosimilars are:
- dosing regimen claims that map to the label,
- and formulation/device claims that map to the exact presentation at launch.
What patents protect abaloparatide (PTHrP analog) and how does that affect entry risk?
Answer (featured snippet): Abaloparatide’s patent estate typically raises the highest entry barrier through regimen/dosing claims and formulation stabilization claims that are difficult to design around while keeping the same injectability and stability profile.
Patent buckets expected to be most commercially relevant
- Method-of-use and regimen: daily administration with defined duration and patient selection can be claim-protected in key jurisdictions.
- Peptide analog definition: analog sequence claims and salts are often early barriers that expire later than expected.
- Formulation stability: aggregation control, excipient system, and container-closure compatibility can be the last remaining “presentation” bottlenecks.
Design-around constraints
- A product can change:
- excipients and device materials,
- but it must preserve pharmacokinetics and stability targets.
- That trade-off increases the probability that remaining patents become relevant to:
- equivalence studies,
- and launch timing.
When do exclusivity and key patent terms for ATC H05AA products expire?
Answer (featured snippet): H05AA exclusivity timelines are product-specific, but market transitions usually occur in two steps: first after the reference composition and core use patents expire, then after formulation/device and secondary patents expire or are cleared through litigation settlements or design-around.
How to read H05AA timelines in practice
For each reference product, the “time-to-entry” clock is driven by:
- Primary composition expiration (earliest gate).
- Secondary use/regimen patents (often extend effective exclusivity for line extensions).
- Formulation/device patents (delay actual launch presentation even after legal clearance).
- Regulatory submission and approval lead time (manufacturing transfer, stability, and label negotiations).
What matters for investors and generic strategy
- The market rewards entry that is:
- legally clean for the exact label and presentation,
- and operationally ready for the dosing and device constraints.
- Patents that affect only minor presentation elements can still shift launch months to years because payers may require switching stability and consistent experience.
(No specific expiration dates are provided here because the underlying product-by-product patent term dataset is not included in the prompt.)
What Orange Book status applies to H05AA parathyroid hormone products?
Answer (featured snippet): In practice, Orange Book entries for H05AA products determine generic timing where the same active ingredient, dosage form, and strength are targeted. Remaining listed patents on the reference drug are the principal obstacle to Paragraph IV-type strategies.
Practical consequences of Orange Book listings
- If key formulation or use patents remain listed for the same submission-relevant product codes, a generic applicant is exposed to:
- infringement litigation,
- delayed approval,
- and settlement-driven “carve-out” restrictions (often around label language or presentation).
Where Orange Book data is used in H05AA strategy
- Claim chart alignment to:
- listed patents per reference product,
- and the generic’s proposed formulation/dosing.
- Market strategy alignment to:
- payer substitution and channel adoption,
- and device presentation match.
(No Orange Book patent list is reproduced here because the prompt does not provide reference product identifiers or the underlying Orange Book extracts.)
Are there Paragraph IV challenges or biosimilar-style risks in ATC H05AA?
Answer (featured snippet): Entry risk in H05AA is less about classic small-molecule Paragraph IV dynamics and more about “presentation and regimen” barriers, especially for biologic-like peptides and for line extensions where remaining method-of-use claims still map tightly to label.
Challenge vectors typically seen in H05AA
- Patent infringement via dosing regimen mapping
- Formulation or stability patent infringement for the exact injectable presentation
- Device integration claims
- Manufacturing process claims affecting impurity profiles and stability
Why biosimilar-style risk can still matter
Even when a product is positioned as a follow-on peptide rather than a full biosimilar in all jurisdictions, the patent landscape still treats:
- peptide sequence definition,
- method-of-use,
- and formulation stability as key determinants of whether a court or regulator accepts design-around changes.
(No specific case list is provided because the prompt does not include litigation docket identifiers or patent numbers.)
Which companies are leading in H05AA and what does the patent estate imply about their competitive positions?
Answer (featured snippet): The competitive leaders for H05AA generally align with the incumbents that control core peptide claims and the formulation/device ecosystem, while followers compete where patents expire or can be designed around without disrupting injectability and stability.
Typical strategic profiles
- Incumbent manufacturers
- defend the core composition and regimen scope,
- and extend effective exclusivity with formulation and device patents tied to the commercial product presentation.
- Follower manufacturers
- focus on navigating:
- device-formulation compatibility claims,
- and label regimen alignment for osteoporosis care pathways.
- focus on navigating:
Patent estate implications for competitive positioning
- Strong estates shift the competitive timeline from “regulatory readiness” to “IP clearance readiness.”
- Weaker estates shift competition toward speed of scale-up and procurement economics.
(No company-specific portfolio list is provided because the prompt does not include named products and jurisdictions.)
How do formulation and device patents affect generic or follow-on launch timelines in H05AA?
Answer (featured snippet): Formulation and device patents often become the last mile that delays launch, even after composition and basic use patents expire, because substitutes must keep the same injectability, stability, and user interface.
Formulation patent mechanisms
- Control aggregation and surface adsorption
- Maintain viscosity and pH range during shelf life
- Preserve stability through container-closure interactions
Device patent mechanisms
- Needle and cartridge flow path design
- Material compatibility to prevent adsorption/peptide loss
- Pen mechanism ensuring consistent dose delivery
Business impact
- If a competitor redesigns the device or excipient system, they may need:
- additional stability studies,
- bridging clinical or bioequivalence work,
- and label negotiations, all of which move launch dates beyond exclusivity expiry.
How does ATC H05AA patent strength compare between teriparatide and abaloparatide?
Answer (featured snippet): Patent strength comparison in H05AA is usually strongest where the incumbent has multiple overlapping secondary patents across dosing regimens, formulation stability, and device integration. The winner is typically the product with the densest set of still-listed enforceable patents close to launch.
What to compare (structurally)
- Number of enforceable:
- composition claims,
- method-of-use/regimen claims,
- formulation stability claims,
- and device/presentation claims in major markets.
- Remaining enforceability time windows relative to expected regulatory submission and scale-up.
(No quantitative patent count per product is provided because the prompt does not include a jurisdictional patent inventory.)
What generic entry risks exist for ATC H05AA after exclusivity?
Answer (featured snippet): Entry risks concentrate in the exact-match areas: the proposed product’s regimen alignment, the formulation’s stabilization system, and the device presentation. Even small deviations can be pinned down by claim scope if the patent estate is drafted broadly.
Common entry risk triggers
- Label language matches a method-of-use claim
- Formulation excipient system or stabilization logic matches a claim
- Device architecture is found to be equivalent in function/structure
- Manufacturing process or impurity profile overlaps a process claim
Mitigations competitors typically use
- Designing around:
- excipient composition and concentrations,
- device flow path geometry,
- container-closure materials.
- Narrowing label to reduce method-of-use overlap.
- Negotiating settlements that specify launch timing and/or label carve-outs.
(No actual settlements or litigation outcomes are provided because the prompt lacks case identifiers.)
What manufacturing and IP barriers slow down H05AA follow-on development?
Answer (featured snippet): For injectable peptides and analogs, the tight coupling between peptide stability, excipient formulation, and container/device compatibility increases both technical development time and the probability that remaining patents map onto the follow-on’s final commercial presentation.
Manufacturing barriers
- Maintaining peptide integrity (aggregation/fragmentation control)
- Achieving stable viscosity and pH targets for pen injection
- Ensuring container-closure compatibility that avoids adsorption losses
IP barriers
- Process patents that constrain specific manufacturing steps or controls
- Formulation claims that constrain stabilization systems
- Device claims that constrain integration design
Key takeaways
- ATC H05AA market transitions are driven by a two-step exclusivity pattern: core composition/use expiry first, then formulation and device patents that delay presentation-accurate launch.
- The highest entry risks for teriparatide-like peptides and PTHrP analogs are those that map to label-aligned dosing regimens and the exact injectable presentation.
- Formulation and device patents are often the last mile controlling how fast follow-on products can reach pharmacy shelves with the same clinical usability.
FAQs
1) What does “presentation” mean for patent risk in H05AA injectable peptides?
Presentation is the combination of active ingredient, strength, excipient system, container-closure, and device interface. H05AA follow-on products face infringement risk when claims cover that full presentation.
2) Do method-of-use patents matter if a follow-on has the same active ingredient?
Yes. If the method-of-use or dosing regimen claims track the label or standard clinical regimen, the follow-on can be blocked even with expired composition patents.
3) Can switching pens or injection devices avoid H05AA device patents?
Only if the device changes avoid claim scope or equivalence tests. Device redesign must also preserve dose delivery precision and peptide stability, which can trigger additional development time.
4) What is the biggest reason H05AA launches slip after exclusivity expiry?
Presentation readiness under the patent estate, especially formulation-device stabilization constraints and label negotiations tied to method-of-use risk.
5) Are H05AA follow-on products mainly limited by regulatory review or by IP?
IP is usually the gating factor when Orange Book-listed or enforceable patents remain for the exact product code and presentation. Regulatory review still becomes a bottleneck when IP design-around requires extra bridging work.
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
More… ↓
